GlassScriptPhysician profile
Michael S Misuraca
NPI 1982826699
$10,394.62
in general payments reported to CMS, 2019-2025
30 companies · $1,500 in 2025
The $1,500 reported for 2025 was more than what 86% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,803 · 2020: $1,093 · 2021: $1,012 · 2022: $1,523 · 2023: $1,722 · 2024: $1,742 · 2025: $1,500.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,787 · Education: $176.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,787.43 |
| Education | $176.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vifor Pharma, INC. | $1,316.00 | 2019-2024 | Veltassa, Korsuva |
| Astrazeneca Pharmaceuticals LP | $882.33 | 2019-2025 | Lokelma, Farxiga |
| Travere Therapeutics, INC. | $854.20 | 2021-2025 | Filspari |
| Otsuka America Pharmaceutical, INC. | $818.09 | 2019-2025 | Jynarque |
| Bayer Healthcare Pharmaceuticals INC. | $694.18 | 2021-2025 | |
| Amgen INC. | $550.81 | 2019-2025 | Tavneos, Krystexxa |
| Alexion Pharmaceuticals, INC. | $539.32 | 2019-2025 | Ultomiris |
| Mallinckrodt Hospital Products INC. | $519.25 | 2020-2025 | Acthar, Terlivaz |
| Aurinia Pharma U.S., INC. | $512.10 | 2021-2025 | Lupkynis |
| Akebia Therapeutics INC | $436.50 | 2019-2025 | Vafseo, Auryxia |
| Calliditas Therapeutics US INC. | $399.11 | 2022-2025 | Tarpeyo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $328.29 | 2024-2025 | Jardiance |
| Opko Pharmaceuticals, LLC | $309.93 | 2019-2025 | Rayaldee |
| Glaxosmithkline, LLC. | $304.68 | 2021-2025 | Benlysta, Jesduvroq |
| Mallinckrodt Enterprises LLC | $302.39 | 2019 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fresenius USA Marketing, INC. | $295.83 | 2019-2024 | Velphoro, Korsuva |
| Genzyme Corporation | $279.79 | 2019-2024 | |
| Novo Nordisk INC | $241.54 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $202.80 | 2019-2025 | |
| Horizon Therapeutics Plc | $166.13 | 2019-2022 | |
| Ardelyx, INC. | $146.65 | 2024-2025 | Ibsrela |
| Lundbeck LLC | $129.94 | 2019 | |
| Apellis Pharmaceuticals, INC. | $46.00 | 2025 | Empaveli |
| Kyowa Kirin, INC. | $21.34 | 2025 | |
| Daiichi Sankyo INC. | $20.37 | 2022 | |
| Alnylam Pharmaceuticals INC. | $20.33 | 2023 | Oxlumo |
| Ani Pharmaceuticals, INC. | $17.25 | 2023 | Purified Cortrophin Gel |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $15.99 | 2025 | |
| Nxstage Medical, INC. | $11.78 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $11.70 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Misuraca listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.